PGGM Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
– Sell
-90,762
Closed -$13.9M – 454
2021
Q1
$13.9M Sell
90,762
-88,093
-49% -$13.6M 0.06% 252
2020
Q4
$27.9M Sell
178,855
-247,308
-58% -$31.8M 0.13% 184
2020
Q3
$48.8M Buy
426,163
+98,956
+30% +$10.7M 0.25% 93
2020
Q2
$36.7M Buy
+327,207
New +$34.7M 0.21% 116

Other funds holding ALXN

PGGM Investments's ALXN Position: Q2 2021 in Review

PGGM Investments sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 90,762 shares — an estimated $13.9M sold.

PGGM Investments first reported a position in ALXN in Q2 2020 and held it in 4 quarters. The position peaked at $48.8M in Q3 2020. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • PGGM Investments reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • PGGM Investments sold 90,762 Alexion Pharmaceuticals shares in Q2 2021, an estimated $13.9M.
  • PGGM Investments first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • PGGM Investments's Alexion Pharmaceuticals position peaked at $48.8M in Q3 2020.
  • 710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on PGGM Investments's 13F filing for Q2 2021, filed 22 Jul 2021.